Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Quinolines"" wg kryterium: Temat


Tytuł:
Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data.
Autorzy:
Otani Y; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.
Kasai H; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.
Tanigawara Y; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Mar; Vol. 10 (3), pp. 188-198. Date of Electronic Publication: 2021 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Hypertension/*chemically induced
Phenylurea Compounds/*pharmacokinetics
Product Surveillance, Postmarketing/*methods
Protein Kinase Inhibitors/*pharmacokinetics
Quinolines/*pharmacokinetics
Thyroid Neoplasms/*drug therapy
Aged ; Angiotensin Receptor Antagonists/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Antihypertensive Agents/pharmacology ; Area Under Curve ; Blood Pressure/drug effects ; Calcium Channel Blockers/pharmacology ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; Hypertension/drug therapy ; Japan/epidemiology ; Male ; Middle Aged ; Phenylurea Compounds/administration & dosage ; Phenylurea Compounds/adverse effects ; Phenylurea Compounds/pharmacology ; Product Surveillance, Postmarketing/statistics & numerical data ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology ; Quinolines/administration & dosage ; Quinolines/adverse effects ; Quinolines/pharmacology ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Tytuł:
Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males.
Autorzy:
Kruithof AC; Centre for Human Drug Research, Leiden, The Netherlands.
Kumar R; Dr. Reddy's Laboratories Ltd, Hyderabad, India.
Stevens J; Centre for Human Drug Research, Leiden, The Netherlands.
de Kam ML; Centre for Human Drug Research, Leiden, The Netherlands.
Gautam A; Dr. Reddy's Laboratories SA, Basel, Switzerland.
Alikunju S; Dr. Reddy's Laboratories Ltd, Hyderabad, India.
Padhi BK; Dr. Reddy's Laboratories Ltd, Hyderabad, India.
Kulkarni S; Dr. Reddy's Laboratories Ltd, Hyderabad, India.
Raghuvanshi RS; Dr. Reddy's Laboratories Ltd, Hyderabad, India.
Gandhi R; Dr. Reddy's Laboratories Ltd, Hyderabad, India.
Burggraaf J; Centre for Human Drug Research, Leiden, The Netherlands.
Kamerling IMC; Centre for Human Drug Research, Leiden, The Netherlands.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 Nov; Vol. 8 (8), pp. 1042-1052. Date of Electronic Publication: 2019 Jun 10.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Food-Drug Interactions*
Cholesterol Ester Transfer Proteins/*antagonists & inhibitors
Quinolines/*pharmacokinetics
Tetrazoles/*pharmacokinetics
Administration, Oral ; Adolescent ; Adult ; Area Under Curve ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Cross-Over Studies ; Dietary Fats/administration & dosage ; Dietary Fats/adverse effects ; Drug Compounding ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Quinolines/administration & dosage ; Quinolines/blood ; Tetrazoles/administration & dosage ; Tetrazoles/blood ; Triglycerides/blood ; Young Adult
Czasopismo naukowe
Tytuł:
Gene-dosage effect of Pfkfb3 on monocyte/macrophage biology in atherosclerosis.
Autorzy:
Guo S; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Li A; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.; Department of Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Fu X; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Li Z; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Cao K; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Song M; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Huang S; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Li Z; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Yan J; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Wang L; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.; Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Dai X; Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Feng D; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Wang Y; College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
He J; Department of Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Huo Y; Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
Xu Y; School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2022 Nov; Vol. 179 (21), pp. 4974-4991. Date of Electronic Publication: 2022 Aug 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Atherosclerosis*/drug therapy
Atherosclerosis*/genetics
Atherosclerosis*/metabolism
Monocytes*/metabolism
Actins/metabolism ; Animals ; Apolipoproteins E/genetics ; Apolipoproteins E/metabolism ; Biology ; Macrophages ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Phosphofructokinase-2 ; Pyridines ; Quinolines
Czasopismo naukowe
Tytuł:
Preclinical evaluation of [ F]MA3: a CB 2 receptor agonist radiotracer for PET.
Autorzy:
Attili B; Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Celen S; Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Ahamed M; Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Koole M; Department of Nuclear Medicine and Molecular Imaging, UZ Gasthuisberg, Leuven, Belgium.
Haute CVD; Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Leuven, Belgium.; Leuven Viral Vector Core, Molecular Medicine, KU Leuven, Leuven, Belgium.
Vanduffel W; Laboratory for Neuro- and Psychophysiology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Bormans G; Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2019 May; Vol. 176 (10), pp. 1481-1491. Date of Electronic Publication: 2019 Jan 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Radiopharmaceuticals*
Cannabinoid Receptor Agonists/*metabolism
Positron-Emission Tomography/*methods
Quinolines/*metabolism
Receptor, Cannabinoid, CB2/*metabolism
Animals ; Autoradiography/methods ; Brain/diagnostic imaging ; Brain/metabolism ; Cannabinoid Receptor Agonists/blood ; Cannabinoid Receptor Agonists/chemical synthesis ; Drug Evaluation, Preclinical ; Macaca mulatta ; Protein Binding ; Quinolines/chemical synthesis ; Rats ; Receptor, Cannabinoid, CB2/genetics
Czasopismo naukowe
Tytuł:
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Autorzy:
Kintscher U; Institute of Pharmacology, Cardiovascular-Metabolic-Renal Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
Bakris GL; Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, Illinois, USA.
Kolkhof P; Research & Early Development, Cardiovascular Research, Bayer AG, Wuppertal, Germany.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2022 Jul; Vol. 179 (13), pp. 3220-3234. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/chemically induced
Heart Failure*/drug therapy
Mineralocorticoid Receptor Antagonists*/pharmacology
Mineralocorticoid Receptor Antagonists*/therapeutic use
Humans ; Hypertension, Renal ; Mineralocorticoids/therapeutic use ; Nephritis ; Piperidines/therapeutic use ; Pyrazoles/therapeutic use ; Quinolines
SCR Disease Name:
Hypertensive Nephropathy
Czasopismo naukowe
Tytuł:
Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Autorzy:
Yang H; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Merica E; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Chen Y; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Cohen M; MBC Pharma Solutions, Newtown, PA, USA.
Goldwater R; PAREXEL International, Baltimore, MD, USA.
Kosinski PA; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Kung C; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Yuan ZJ; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Silverman L; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Goldwasser M; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Silver BA; Bruce A Silver Clinical Science and Development, Dunkirk, MD, USA.
Agresta S; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Barbier AJ; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 Feb; Vol. 8 (2), pp. 246-259. Date of Electronic Publication: 2018 Aug 09.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Piperazines/*administration & dosage
Piperazines/*pharmacokinetics
Quinolines/*administration & dosage
Quinolines/*pharmacokinetics
Adult ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Female ; Glycolysis ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Piperazines/adverse effects ; Quinolines/adverse effects
Czasopismo naukowe
Tytuł:
Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.
Autorzy:
Hsyu PH; Pfizer Inc, La Jolla, CA, USA.
Pignataro DS; Pfizer Inc, Walton Oaks, Surrey, UK.
Matschke K; Pfizer Inc, Collegeville, PA, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2018 May; Vol. 7 (4), pp. 373-381. Date of Electronic Publication: 2017 Oct 23.
Typ publikacji:
Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Aniline Compounds/*administration & dosage
Aniline Compounds/*pharmacokinetics
Nitriles/*administration & dosage
Nitriles/*pharmacokinetics
Quinolines/*administration & dosage
Quinolines/*pharmacokinetics
Administration, Intravenous ; Administration, Oral ; Adult ; Aniline Compounds/adverse effects ; Area Under Curve ; Biological Availability ; Cross-Over Studies ; Drug Administration Schedule ; Female ; Half-Life ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Nitriles/adverse effects ; Quinolines/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł:
Comparative Pharmacokinetics Between a Fixed-Dose Combination of Pitavastatin/Valsartan 4/160 mg and the Corresponding Individual Components Through a Partial Replicated Crossover Design in Healthy Male Subjects.
Autorzy:
Na JY; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Yang E; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Kim JH; Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Chungnam National University Hospital, Daejeon, Republic of Korea.
Kwon IS; Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Chungnam National University Hospital, Daejeon, Republic of Korea.
Jin EH; Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
Yu KS; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Kim J; JW Pharmaceutical Corporation, Seoul, Republic of Korea.
Lee S; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Hong JH; Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Chungnam National University Hospital, Daejeon, Republic of Korea.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 May; Vol. 11 (5), pp. 615-622. Date of Electronic Publication: 2022 Jan 08.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Cross-Over Studies*
Drug Combinations ; Healthy Volunteers ; Humans ; Male ; Quinolines ; Valsartan
Czasopismo naukowe
Tytuł:
Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers.
Autorzy:
Dennison J; Hammersmith Medicines Research, Cumberland Avenue, London, England.
Puri A; Hammersmith Medicines Research, Cumberland Avenue, London, England.
Warrington S; Hammersmith Medicines Research, Cumberland Avenue, London, England.
Endo T; Maruho Co Ltd, Kyoto, Japan.
Adeloye T; Hammersmith Medicines Research, Cumberland Avenue, London, England.
Johnston A; Analytical Services International Ltd, St. George's-University of London, Cranmer Terrace, London, England.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2018 Nov; Vol. 7 (8), pp. 860-870. Date of Electronic Publication: 2018 Jun 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Acetates/*pharmacokinetics
Bupropion/*pharmacokinetics
Cytochrome P-450 CYP2B6/*metabolism
Cytochrome P-450 CYP2C8/*metabolism
Oxadiazoles/*pharmacokinetics
Quinolines/*pharmacokinetics
Acetates/blood ; Adolescent ; Adult ; Bupropion/blood ; Cyclopropanes ; Cytochrome P-450 CYP2B6/biosynthesis ; Cytochrome P-450 CYP2B6 Inducers/blood ; Cytochrome P-450 CYP2B6 Inducers/pharmacokinetics ; Cytochrome P-450 CYP2B6 Inducers/pharmacology ; Cytochrome P-450 CYP2C8 Inhibitors/blood ; Cytochrome P-450 CYP2C8 Inhibitors/pharmacokinetics ; Cytochrome P-450 CYP2C8 Inhibitors/pharmacology ; Drug Interactions ; Healthy Volunteers ; Hepatocytes/metabolism ; Humans ; Male ; Middle Aged ; Oxadiazoles/blood ; Oxadiazoles/pharmacology ; Quinolines/blood ; Sulfides ; Young Adult
Czasopismo naukowe
Tytuł:
Toxic epidermal necrolysis induced by cystic fibrosis transmembrane conductance regulator modulators.
Autorzy:
Mederos-Luis E; Allergy Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
González-Pérez R; Allergy Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Poza-Guedes P; Allergy Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Álava-Cruz C; Allergy Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Matheu V; Allergy Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Sánchez-Machín I; Allergy Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Pokaż więcej
Źródło:
Contact dermatitis [Contact Dermatitis] 2022 Mar; Vol. 86 (3), pp. 224-225. Date of Electronic Publication: 2021 Nov 30.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Aminophenols/*adverse effects
Benzodioxoles/*adverse effects
Indoles/*adverse effects
Membrane Transport Modulators/*adverse effects
Pyrazoles/*adverse effects
Pyridines/*adverse effects
Quinolines/*adverse effects
Stevens-Johnson Syndrome/*etiology
Adult ; Drug Combinations ; Humans ; Male ; Stevens-Johnson Syndrome/diagnosis
Czasopismo naukowe
Tytuł:
Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.
Autorzy:
McCrea JB; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Hussain A; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Ma B; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Garrett GC; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Evers R; Merck & Co., Inc., Kenilworth, New Jersey, USA.; Johnson & Johnson, Janssen Pharmaceuticals, Springhouse, Pennsylvania, USA.
Laabs JE; Celerion, 2420 W. Baseline Road, Tempe, Arizona, USA.
Stoch SA; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Iwamoto M; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Mar; Vol. 11 (3), pp. 406-412. Date of Electronic Publication: 2021 Nov 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Purinergic P2X Receptor Antagonists*/adverse effects
Receptors, Purinergic P2X3*
Adolescent ; Adult ; Humans ; Middle Aged ; Pharmaceutical Preparations ; Pyrimidines ; Quinolines ; Sulfonamides ; Young Adult
Czasopismo naukowe
Tytuł:
Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease.
Autorzy:
Yu JS; Department of Agricultural Biotechnology, Center for Food and Bioconvergence, Research Institute for Agricultural and Life Sciences, Seoul National University, Seoul, Republic of Korea.
Youn GS; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Choi J; Department of Agricultural Biotechnology, Center for Food and Bioconvergence, Research Institute for Agricultural and Life Sciences, Seoul National University, Seoul, Republic of Korea.
Kim CH; Department of Agricultural Biotechnology, Center for Food and Bioconvergence, Research Institute for Agricultural and Life Sciences, Seoul National University, Seoul, Republic of Korea.
Kim BY; ChunLab, Inc., Seoul, Republic of Korea.
Yang SJ; ChunLab, Inc., Seoul, Republic of Korea.
Lee JH; ChunLab, Inc., Seoul, Republic of Korea.
Park TS; Department of Life Science, Gachon University, Sungnam, Republic of Korea.
Kim BK; Chong Kun Dang Bio Research Institute, Gyeonggi-do, Republic of Korea.
Kim YB; Department of Agricultural Biotechnology, Center for Food and Bioconvergence, Research Institute for Agricultural and Life Sciences, Seoul National University, Seoul, Republic of Korea.; Microbiology and Functionality Research Group, World Institute of Kimchi, Gwangju, Republic of Korea.
Roh SW; Microbiology and Functionality Research Group, World Institute of Kimchi, Gwangju, Republic of Korea.
Min BH; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Park HJ; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Yoon SJ; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Lee NY; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Choi YR; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Kim HS; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Gupta H; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Sung H; School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Han SH; Department of Pathology, Hallym University College of Medicine, Chuncheon, Republic of Korea.
Suk KT; Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.
Lee DY; Department of Agricultural Biotechnology, Center for Food and Bioconvergence, Research Institute for Agricultural and Life Sciences, Seoul National University, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2021 Dec; Vol. 11 (12), pp. e634.
Typ publikacji:
Journal Article
MeSH Terms:
Cellular Reprogramming/*immunology
Gastrointestinal Microbiome/*immunology
Lactobacillus/*metabolism
Metabolome/*immunology
Non-alcoholic Fatty Liver Disease/*drug therapy
Pediococcus pentosaceus/*metabolism
Animals ; Benzofurans/metabolism ; Cellular Reprogramming/physiology ; Diet, Western/adverse effects ; Disease Models, Animal ; Feces/microbiology ; Gastrointestinal Microbiome/physiology ; Lactobacillus/pathogenicity ; Metabolome/physiology ; Mice ; Non-alcoholic Fatty Liver Disease/physiopathology ; Pediococcus pentosaceus/pathogenicity ; Quinolines/metabolism
SCR Organism:
Lactobacillus delbrueckii subsp. lactis
Czasopismo naukowe
Tytuł:
Montelukast reduces inhaled chlorine triggered airway hyperresponsiveness and airway inflammation in the mouse.
Autorzy:
Hamamoto Y; Meakins-Christie Laboratories, The Research Institute of McGill University Health Centre and the Department of Medicine, McGill University, Montreal, QC, Canada.
Ano S; Meakins-Christie Laboratories, The Research Institute of McGill University Health Centre and the Department of Medicine, McGill University, Montreal, QC, Canada.
Allard B; Meakins-Christie Laboratories, The Research Institute of McGill University Health Centre and the Department of Medicine, McGill University, Montreal, QC, Canada.
O'Sullivan M; Meakins-Christie Laboratories, The Research Institute of McGill University Health Centre and the Department of Medicine, McGill University, Montreal, QC, Canada.
McGovern TK; Meakins-Christie Laboratories, The Research Institute of McGill University Health Centre and the Department of Medicine, McGill University, Montreal, QC, Canada.
Martin JG; Meakins-Christie Laboratories, The Research Institute of McGill University Health Centre and the Department of Medicine, McGill University, Montreal, QC, Canada.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2017 Oct; Vol. 174 (19), pp. 3346-3358. Date of Electronic Publication: 2017 Aug 23.
Typ publikacji:
Journal Article
MeSH Terms:
Acetates/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Chlorine/*toxicity
Irritants/*toxicity
Leukotriene Antagonists/*therapeutic use
Quinolines/*therapeutic use
Respiratory Hypersensitivity/*drug therapy
Acetates/pharmacology ; Animals ; Anti-Inflammatory Agents/pharmacology ; Antibodies, Monoclonal/pharmacology ; Bronchoalveolar Lavage Fluid/immunology ; Cell Line ; Cyclopropanes ; Cytokines/immunology ; Leukotriene Antagonists/pharmacology ; Lung/drug effects ; Lung/metabolism ; Male ; Mice, Inbred BALB C ; NF-E2-Related Factor 2/metabolism ; Quinolines/pharmacology ; Receptors, Interleukin-6/immunology ; Respiratory Hypersensitivity/chemically induced ; Sulfides
Czasopismo naukowe
Tytuł:
Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.
Autorzy:
Luangmonkong T; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.; Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Suriguga S; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
Bigaeva E; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
Boersema M; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
Oosterhuis D; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
de Jong KP; Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, The Netherlands.
Schuppan D; Institute of Translational Immunology and Research Center for Immunotherapy, University of Mainz Medical Center, Mainz, Germany.; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Mutsaers HAM; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
Olinga P; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2017 Sep; Vol. 174 (18), pp. 3107-3117. Date of Electronic Publication: 2017 Aug 11.
Typ publikacji:
Journal Article
MeSH Terms:
Liver Cirrhosis/*drug therapy
Pyrazoles/*pharmacology
Quinolines/*pharmacology
Smad2 Protein/*antagonists & inhibitors
Animals ; Dose-Response Relationship, Drug ; Humans ; Liver Cirrhosis/metabolism ; Male ; Phosphorylation/drug effects ; Pyrazoles/chemistry ; Quinolines/chemistry ; Rats ; Rats, Wistar ; Smad2 Protein/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł:
Radiosynthesis of novel pitavastatin derivative ([ F]PTV-F1) as a tracer for hepatic OATP using a one-pot synthetic procedure.
Autorzy:
Kimura H; Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.; Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, Japan.
Yagi Y; Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.
Arimitsu K; Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.; Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, Japan.
Maeda K; Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Ikejiri K; Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Takano JI; Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Kusuhara H; Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Kagawa S; Shiga Medical Center Research Institute, Moriyama, Moriyama City, Shiga, Japan.
Ono M; Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.
Sugiyama Y; Sugiyama Laboratory, RIKEN Innovation Center, RIKEN Cluster for Industry Partnerships, RIKEN, Tsurumi-ku, Yokohama, Japan.
Saji H; Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.
Pokaż więcej
Źródło:
Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2016 Nov; Vol. 59 (13), pp. 565-575. Date of Electronic Publication: 2016 Oct 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Chemistry Techniques, Synthetic/*methods
Fluorine Radioisotopes/*chemistry
Liver/*metabolism
Organic Anion Transporters/*metabolism
Quinolines/*chemical synthesis
Quinolines/*metabolism
Radiochemistry/*methods
Biological Transport ; Quinolines/chemistry
Czasopismo naukowe
Tytuł:
A report of the automated radiosynthesis of the tau positron emission tomography radiopharmaceutical, [ F]-THK-5351.
Autorzy:
Neelamegam R; Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.; Department of Radiology, Harvard Medical School, Boston, MA, USA.
Yokell DL; Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.; Department of Radiology, Harvard Medical School, Boston, MA, USA.
Rice PA; Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Furumoto S; Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.
Kudo Y; Division of Neuro-imaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Okamura N; Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
El Fakhri G; Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.; Department of Radiology, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło:
Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2017 Feb; Vol. 60 (2), pp. 140-146. Date of Electronic Publication: 2017 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Aminopyridines/*chemical synthesis
Quinolines/*chemical synthesis
Radiopharmaceuticals/*chemical synthesis
Aminopyridines/chemistry ; Automation/methods ; Chemistry Techniques, Synthetic/methods ; Quinolines/chemistry ; Radiopharmaceuticals/chemistry
Czasopismo naukowe
Tytuł:
Erythroderma caused by allergic contact dermatitis from Solvent Yellow 33 in a patient with psoriasis.
Autorzy:
Gatica-Ortega ME; Department of Dermatology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Pastor-Nieto MA; Department of Dermatology, Hospital Universitario de Guadalajara, Guadalajara, Spain.; Faculty of Medicine and Health Sciences, Medicine and Medical Specialties Department, Universidad de Alcalá, Alcalá de Henares, Spain.
Sánchez-Matas I; Department of Allergy, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Torres-Aranda R; Department of Dermatology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Vergara-de-la-Campa L; Department of Dermatology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Martínez-Camacho M; Department of Pharmacy, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Pérez-Hortet C; Department of Dermatology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Pokaż więcej
Źródło:
Contact dermatitis [Contact Dermatitis] 2021 Jun; Vol. 84 (6), pp. 454-456. Date of Electronic Publication: 2020 Dec 21.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Dermatitis, Allergic Contact/*etiology
Dermatitis, Exfoliative/*chemically induced
Psoriasis/*drug therapy
Quinolines/*adverse effects
Adrenal Cortex Hormones/therapeutic use ; Dermatitis, Allergic Contact/drug therapy ; Dermatitis, Exfoliative/drug therapy ; Humans ; Male ; Middle Aged ; Patch Tests ; Plant Oils/adverse effects ; Psoriasis/complications
Czasopismo naukowe
Tytuł:
Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.
Autorzy:
Zeigler AC; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
Chandrabhatla AS; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
Christiansen SL; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
Nelson AR; Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
Holmes JW; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.; Division of Cardiovascular Medicine, University of Virginia, Charlottesville, Virginia, USA.
Saucerman JJ; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.; Division of Cardiovascular Medicine, University of Virginia, Charlottesville, Virginia, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Apr; Vol. 10 (4), pp. 377-388. Date of Electronic Publication: 2021 Feb 27.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Aminobutyrates/*pharmacology
Angiotensin Receptor Antagonists/*pharmacology
Biphenyl Compounds/*pharmacology
Pyrazoles/*pharmacology
Quinolines/*pharmacology
Receptors, Transforming Growth Factor beta/*antagonists & inhibitors
Valsartan/*pharmacology
Animals ; Arsenic Trioxide/adverse effects ; Computer Simulation ; Drug Combinations ; Fibroblasts/drug effects ; Fibroblasts/metabolism ; Fibrosis/chemically induced ; Fibrosis/diagnosis ; Heart Diseases/pathology ; Humans ; MAP Kinase Signaling System/drug effects ; MAP Kinase Signaling System/genetics ; Matrix Metalloproteinase 2/pharmacology ; Models, Animal ; Network Pharmacology ; Quaternary Ammonium Compounds/pharmacology ; Rats ; Receptors, Transforming Growth Factor beta/metabolism ; Signal Transduction/drug effects ; Smad3 Protein/drug effects ; Smad3 Protein/metabolism ; Thioctic Acid/analogs & derivatives ; Thioctic Acid/pharmacology
Czasopismo naukowe
Tytuł:
The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain.
Autorzy:
Bagdas D; Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.; Experimental Animals Breeding and Research Center, Faculty of Medicine, Uludag University, Bursa, Turkey.
Wilkerson JL; Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
Kulkarni A; Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Toma W; Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
AlSharari S; Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.; Department of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia.
Gul Z; Department of Pharmacology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Lichtman AH; Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
Papke RL; Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA.
Thakur GA; Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Damaj MI; Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2016 Aug; Vol. 173 (16), pp. 2506-20. Date of Electronic Publication: 2016 Jul 18.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Disease Models, Animal*
Inflammation/*drug therapy
Neuralgia/*drug therapy
Neuralgia/*prevention & control
Quinolines/*pharmacology
Sulfonamides/*pharmacology
alpha7 Nicotinic Acetylcholine Receptor/*agonists
Allosteric Regulation/drug effects ; Animals ; Dose-Response Relationship, Drug ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Inbred ICR ; Quinolines/administration & dosage ; Structure-Activity Relationship ; Sulfonamides/administration & dosage
Czasopismo naukowe
Tytuł:
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Autorzy:
Cotreau MM; AVEO Oncology, Cambridge, MA, USA.
Siebers NM; Covance, Madison, WI, USA.; Covance, Daytona, FL, USA.
Miller J; AVEO Oncology, Cambridge, MA, USA.
Strahs AL; AVEO Oncology, Cambridge, MA, USA.
Slichenmyer W; AVEO Oncology, Cambridge, MA, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2015 Mar; Vol. 4 (2), pp. 137-42. Date of Electronic Publication: 2014 Oct 01.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Angiogenesis Inhibitors/*pharmacokinetics
Cytochrome P-450 CYP3A/*metabolism
Cytochrome P-450 CYP3A Inducers/*administration & dosage
Cytochrome P-450 CYP3A Inhibitors/*administration & dosage
Ketoconazole/*administration & dosage
Phenylurea Compounds/*pharmacokinetics
Protein Kinase Inhibitors/*pharmacokinetics
Quinolines/*pharmacokinetics
Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors
Rifampin/*administration & dosage
Administration, Oral ; Adolescent ; Adult ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/blood ; Area Under Curve ; Biotransformation ; Cytochrome P-450 CYP3A Inducers/adverse effects ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Female ; Half-Life ; Humans ; Ketoconazole/adverse effects ; Male ; Metabolic Clearance Rate ; Middle Aged ; Models, Biological ; Phenylurea Compounds/administration & dosage ; Phenylurea Compounds/adverse effects ; Phenylurea Compounds/blood ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/blood ; Quinolines/administration & dosage ; Quinolines/adverse effects ; Quinolines/blood ; Receptors, Vascular Endothelial Growth Factor/metabolism ; Rifampin/adverse effects ; United States ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies